2026 ASCO Breast Cancer Highlights: persevERA - Takeaways - MDSpire

2026 ASCO Breast Cancer Highlights: persevERA

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the persevERA trial and oral SERDS in metastatic breast cancer.

October 15, 2026

Dana-Farber

Share

1

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the persevERA trial.
2

The discussion focuses on oral selective estrogen receptor degraders in metastatic breast cancer.
3

The context does not provide details about the persevERA trial design.
4

The context does not report persevERA efficacy or safety results.
5

The context does not identify the oral SERD discussed or describe its findings.

Original Source(s)

Dana-Farber

2026 ASCO Breast Cancer Highlights: persevERA

October 15, 2026

Related Content

Hemasphere

Correction to “Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL”

October 5, 2026

Dana-Farber

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.